METex14-Mutated NSCLC: Next Steps in Research
Next steps in clinical research to further explore the potential and appropriate use of targeted therapies to treat patients with METex14-mutated non–small cell lung cancer.
Related Articles
Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy
Experts discuss optimizing TKI selection and sequencing strategies for advanced gastrointestinal stromal tumors (GIST) beyond first-line therapy, focusing on the latest clinical data, molecular characterization,…
Subcutaneous Daratumumab Approaches EU Approval in High-Risk Smoldering Myeloma
The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.
Darolutamide Plus ADT Earns Positive Opinion for European Approval From CHMP in Metastatic Hormone-Sensitive Prostate Cancer
The European Medicines Agency’s CHMP has recommended the approval of darolutamide plus ADT in mHSPC in the European Union.
UM171 Cell Therapy Earns Positive CHMP Opinion for Hematological Malignancies
The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.
CHMP Recommends EU Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.
Nirogacestat Awaits Review Following Positive CHMP Opinion for Desmoid Tumors
The EMA’s Committee for Medicinal Products for Human Use granted a positive opinion for nirogacestat for the treatment of patients with desmoid tumors.
CHMP Recommends Ibrutinib Plus Chemoimmunotherapy for Frontline, Transplant-Eligible Mantle Cell Lymphoma
CHMP recommended ibrutinib plus immunochemotherapy for previously untreated, transplant-eligible mantle cell lymphoma.
Science Clears the Way to Treating the Trickiest Bladder Cancers
Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.
First-in-Human Data Support CISH Knockout Strategy to Enhance TIL Activity, Circumvent ICI Resistance in Metastatic GI Cancers
Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.